Case Report

Plasmapheresis, Rituximab, and Ceftriaxone Provided Lasting Improvement for a 27-Year-Old Adult Male with Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS)

Adam Krouse, Huihua Li, Joseph A. Krenzer, and William Nicholas Rose

Department of Pathology, University of Wisconsin Hospital, 600 Highland Ave, Madison, WI 53792, USA

Correspondence should be addressed to William Nicholas Rose; wrose@uwhealth.org

Received 27 May 2021; Revised 19 October 2021; Accepted 25 October 2021; Published 2 November 2021

Copyright © 2021 Adam Krouse et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) is a specific autoimmune response to group-A streptococcal (GAS) infections in children and adolescents with a sudden onset of neuropsychiatric disorders including obsessive-compulsive disorder (OCD) or tic-like symptoms. We present a case report of a 27-year-old male patient who had lasting improvement with plasmapheresis, rituximab, and ceftriaxone. Our patient first developed sudden psychosis and confusion after GAS infections at age 17. He had elevated anti-streptolysin O (ASO) titers, negative urine drug screen, no ETOH in blood, normal CBC, normal TSH, normal salicylate, normal acetaminophen, and a normal head CT. The tentative diagnosis of PANDAS was made, and the patient was thereafter treated with antipsychotics, antibiotics, tonsillectomy, and IVIG which resulted in remissions and relapses of his neuropsychiatric symptoms. Once he reached age 27, he received a trial of therapeutic plasma exchange (TPE), rituximab, and ceftriaxone. This eventually resulted in sustained benefit and minimal fluctuations of his clinical symptoms. Our report is noteworthy in three ways. One, he is a 27-year-old adult with PANDAS. Two, he improved after TPE, rituximab, and ceftriaxone. Our literature search yielded minimal data on the use of plasmapheresis for nonteenage adults with PANDAS. Three, he had unusual symptoms of PANDAS, as the typical OCD and/or tic-like symptoms were not observed.

1. Introduction

Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) was first described by Swedo et al. in the late 1990s and refers to a disease state characterized by the abrupt onset of neuropsychiatric symptoms. The most common are obsessive-compulsive disorder (OCD) and/or tics. PANDAS is a subtype of pediatric acute-onset neuropsychiatric syndrome (PANS) but with a temporal relationship to infection with beta hemolytic group-A streptococcal (GAS) infection.

Additional common symptoms that have been reported in patients within this diagnostic category include hyperactivity, inattention, psychosis, separation anxiety, behavioral regression, nighttime fears and rituals, decline in school performance, sensory issues, and oppositional behaviors [1]. PANDAS appears to have a male predominance [1].

Although the incidence and prevalence of PANDAS are not known, it is generally considered a rare disease [2]. However, some researchers suggest that it may account for ≥10% of childhood-onset obsessive-compulsive disorder (OCD) and tic disorders [2].

The exact etiology of PANDAS is not well-established. Some strong evidence exists for the role of infection in triggering the symptoms of tics and OCD observed in these patients. ASO titer levels correlate with OCD and tic severity [1].

In addition, PANDAS may also have an autoimmune component. Immunologic aberrations have often been observed in PANDAS patients that include findings similar
to those seen in Sydenham’s chorea (SC), such as evidence of GAS-mediated anti-neuronal autoantibodies, dopamine receptor autoantibodies, and basal ganglia pathology [1].

Given the relatively obscure pathophysiology and variable manifestations, an uncontroversial standard of care does not exist. Selective serotonin reuptake inhibitors (SSRIs) and cognitive behavioral therapy (CBT) are considered first-line therapy for acute-onset OCD spectrum and have been successful in patients with PANDAS [3]. The use of antibiotics is another commonly reported treatment strategy [4–6]. Immunomodulation therapies such as IVIG and plasmapheresis have also been used with some degree of reported success. Plasmapheresis, or therapeutic plasma exchange (TPE), has been shown to be effective in cases of severely ill patients, as demonstrated most recently by Limer et al. in 2015 [7]. Many patients undergo multiple treatment modalities that are often administered in conjunction with one another and with several modifications during their clinical course in an effort to achieve symptom improvement.

2. Case Presentation

We present a 27-year-old-male with PANDAS who received therapeutic plasma exchange (TPE), rituximab, and ceftriaxone with significant improvement. His medical history is notable for asthma, marijuana use, and family history of schizophrenia. Psychiatric family history includes a maternal great grandmother with schizophrenia and a paternal great aunt with an unidentified mental illness requiring institutionalization. About 10 years prior to TPE treatment, the patient was brought to the emergency room by family members for newly developed paranoia and confusion. One month prior to the ER presentation, he had a sore throat, muscle weakness, and fever. His monospot and strep culture were negative. Evaluation at that time revealed normal orientation, anxious mood, mildly restricted affect, and a somewhat tangential and disorganized thought process. His judgement and insight had improved from prior. His family reported that for a few days prior to presentation, the patient had been making some paranoid comments such as believing his water was contaminated. However, these symptoms fluctuated. He was diagnosed with an acute stress reaction, prescribed trazodone to help him sleep, and told to follow up with psychiatry as an outpatient. The next day, the patient’s symptoms returned, and his family was advised to take him to the ER again. He was then admitted to an inpatient adolescent psychiatric unit. An anti-streptolysin O (ASO) antibody test was performed and was elevated at 835 with a reference range of 0-330. He was discharged from the inpatient unit with a tentative diagnosis of PANDAS and was started on aripiprazole, lorazepam, and azithromycin.

Due to side effects, aripiprazole and lorazepam were discontinued. He received further antibiotic treatment with cefdinir and reported improvement which lasted approximately 2 years until he relapsed.

His symptoms of impaired concentration and slowed cognitive processing continued to wax and wane with intermittent treatment of antibiotics and antipsychotics. The symptoms were of such a magnitude that they impaired his ability to work, thus prompting the patient to start intermittent IVIG therapy. He received relief with IVIG therapies but would subsequently relapse.

Additional workup during this time included a head MRI which was normal. A lumbar tap showed a glucose of 79 and a protein of 27. He also had a mild elevation of GAD65, a negative anti-NMDA receptor test, an electroencephalogram only notable for beta activity, and a paraneoplastic battery which was normal.

He was treated with additional IVIG with an induction dose of 2 g/kg and then 0.5 g/kg weekly for maintenance. His maintenance dose was increased to 1 g/kg due to symptom recurrence. He reported significant relief of symptoms at this time. The maintenance dose was spaced out to every 2 weeks and then every month along with the addition of 1,000 mg BID mycophenolate and 30 mg prednisone.

He did relatively well during this time, but he reported fluctuations in his neuropsychiatric symptoms, specifically his ability to concentrate and his cognitive function. He reported that his ability to work was hampered by the decreased cognitive function he felt during these fluctuations. Given the several previous therapies that did not provide lasting improvement along with sparse case reports that plasmapheresis may help with a minimal side effect profile, it was decided to give the patient a trial of TPE.

The IVIG was stopped, his mycophenolate 1000 mg BID was continued, and the prednisone was tapered down to 10 mg a day. TPE was performed 5 times over 11 days on a Monday, Wednesday, Friday (MWF) schedule. The plasmapheresis procedures were all done using centrifugal apheresis machines using 1-plasma volume exchanges with 5% albumin as the replacement fluid. The TPEs were tapered to every 2 weeks. He tolerated the TPEs well.

Due to return of symptoms along with migraine, nausea, and dizziness, the patient again received a series of 5 TPEs over 11 days on a MWF schedule. Patient then transitioned to weekly TPE. He reported that he would feel symptoms return 2-3 days prior to next TPE.

The decision was made to add rituximab to his treatment regimen. He continued weekly TPE and transitioned to...
every 2 weeks and then every 3 weeks. In total, he received 35 TPEs over 11 months. He received 3 infusions of rituximab; the first 2 were 2 weeks apart, and the last one was 6 months later. He received 500 mg IM ceftriaxone weekly which was tapered to every 3 weeks. With the rituximab, TPE, and ceftriaxone, the patient ultimately reported sustained benefit and minimal fluctuations of his symptoms after cessation of the above 3 therapies.

3. Discussion

3.1. Diagnosis. The 5 diagnostic criteria proposed for PANDAS include (1) presence of obsessive-compulsive disorder (OCD) and/or a tic disorder, (2) prepubertal onset, (3) abrupt onset or exacerbation of symptoms with an episodic (relapsing-remitting) course, (4) temporal association of symptoms with GAS infection, and (5) association with neurological abnormalities including choreiform movements [4]. Although the peak age of onset for PANDAS is 6-7 years, PANDAS has also been reported in adults [8]. There are no specific confirmatory laboratory tests. This makes the diagnosis of PANDAS clinically challenging and, to some physicians, controversial.

Positive throat culture result and/or an elevated anti-streptococcal antibody titer following GAS infection support the diagnosis, but many experts claim they are not always present in PANDAS patients. Some authors consider PANDAS to be an autoimmune process, as elevated levels of anti-neuronal antibodies and/or anti-basal ganglia antibodies have been reported [9]. In addition, magnetic resonance imaging (MRI) studies have demonstrated enlargements of the caudate, putamen, and globus pallidus [10]. And, in some patients, the sizes of basal ganglia structures were normalized following successful immunomodulatory therapy with IVIG or plasma exchange [11].

The clinical symptoms of PANDAS can be broad. In addition to OCD and tic-like symptoms, hyperactivity, inattention, psychosis, separation anxiety, behavioral regression, nighttime fears and rituals, decline in school performance, sensory issues, and oppositional behaviors all have been reported in patients who have been diagnosed with PANDAS [12, 13]. No anti-neuronal antibodies or anti-basal ganglia antibodies have been found in this patient. His head MRI also showed relatively normal findings.

We freely concede that, apart from elevated anti-body titers, this patient has no overtly objective findings that definitively prove that he has PANDAS. However, many patients that are labeled with PANDAS as a tentative or working diagnosis also lack many or even any objective findings. Within the relatively immature field of psychiatry (and to some degree, neurology), this is common. In other words, this is not unique to PANDAS, as many neuropsychiatric conditions such as mood, behavioral, and psychotic disorders lack lab tests, imaging, or tissue findings that rule the condition in or out.

Perhaps most importantly, PANDAS itself lacks an uncontroversial definitive set of diagnostic criteria. At minimum, this patient could be said to have a PANDAS-like neuropsychiatric syndrome with a pathophysiology that seems to include ASO antibodies. It could be a separate condition from PANDAS, or splitting them into different labels may simply be a distinction without a difference. We cannot say (nor do we think that anyone in 2021 could say) with certainty.

3.2. Treatment. Currently, the treatment options for PANDAS include cognitive behavioral therapy and/or anti-obsessional medications, antibiotics, tonsillectomy, IVIG, and plasmapheresis. Antibiotic treatment is often indicated in patients with PANDAS with tonsillopharyngitis and a positive GAS throat culture. In a double-blind randomized controlled trial, penicillin and azithromycin prophylaxis was found to be effective in decreasing streptococcal infections and neuropsychiatric symptom exacerbations in children with PANDAS [4, 5].

Surgical interventions, including tonsillectomy and/or adenoidectomy, have been considered in children with PANDAS, although one study has showed that tonsillectomies and adenoidectomies did not prevent the onset of PANDAS [14]. In severely symptomatic patients with PANDAS, immunomodulatory therapies including intravenous immunoglobulin (IVIG) or TPE may be effective in reducing symptom severity or shortening disease course [4, 15].

In addition, Perlmutter et al. reported that plasma exchange and IVIG seemed to be effective in lessening of symptom severity for children with infection-triggered OCD and tic disorders [11]. Latimer et al. studied TPE treatment in 35 severely ill children and adolescents with PANDAS, and they found that all patients appeared to have had at least some benefit with average improvement of 65% at 6-month post-TPE and 78% at longer-term follow-up [7]. TPE as a potentially effective therapy for PANDAS has also been reported from in other case reports [16–18].

In the present case, the patient was initially treated with antipsychotics and antibiotics including azithromycin and cefdinir following the diagnosis of PANDAS. Due to the relapse of the neuropsychiatric symptoms, he then was treated with IVIG and bilateral tonsillectomy followed by TPE, rituximab, and ceftriaxone. Although TPE has been reported as a potential therapy in children and adolescents with PANDAS, the data on TPE for adults with PANDAS is extremely sparse.

His initial doses of TPE resulted in temporary relief and fluctuations of symptoms. With the combination of TPE, rituximab, and ceftriaxone, he eventually achieved sustained benefit and minimal fluctuations of his symptoms. To our knowledge, this specific treatment regimen has not been reported previously with a successful outcome for an adult with PANDAS.

4. Conclusion

We share our experience with a patient with sudden psychosis and confusion after GAS infections who was eventually treated at age 27 with the combination of TPE, rituximab, and ceftriaxone that resulted in sustained benefit and minimal fluctuations of his symptoms that has lasted after the
cessation of treatment. The combination of immunomodulatory therapy (TPE and rituximab) with antibiotics (ceftriaxone) appeared to have worked well in controlling the symptoms in this adult patient with PANDAS. While our data is meager, we offer our report of this patient in case other physicians and patients find it useful.

Abbreviations

TPE: Therapeutic plasma exchange
PANDAS: Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections
OCD: Obsessive–compulsive disorder
ASO: Anti-streptolysin O
IVIG: Intravenous immunoglobulin
GAS: Group-A streptococcus

Data Availability

No data were used to support the findings of this study.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

We thank Dr. Monica Ospina-Romero for her comments that improved the article.

References

[1] T. K. Murphy, D. M. Gerardi, and E. C. Parker-Athill, “The PANDAS controversy: why (and how) is it still unsettled?,” Current Developmental Disorders Reports, vol. 1, no. 4, pp. 236–244, 2014.
[2] F. Jaspers-Fayer, S. H. J. Han, E. Chan et al., "Prevalence of acute-onset subtypes in pediatric obsessive-compulsive disorder," Journal of child and adolescent psychopharmacology, vol. 27, no. 4, pp. 332–341, 2017.
[3] F. Chiarrello, S. Spitoni, E. Hollandier, M. Matucci Cerinic, and S. Pallanti, "An expert opinion on PANDAS/PANS: highlights and controversies," International Journal of Psychiatry in Clinical Practice, vol. 21, no. 2, pp. 91–98, 2017.
[4] A. Padmanabhan, L. Connelly-Smith, N. Aqui et al., "Guidelines on the use of therapeutic apheresis in clinical practice – evidence-based approach from the writing committee of the American Society for Apheresis: the eighth special issue," Journal of Clinical Apheresis, vol. 34, no. 3, pp. 171–354, 2019.
[5] L. A. Snider, L. Lougee, M. Slattery, P. Grant, and S. E. Swedo, "Antibiotic prophylaxis with azithromycin or penicillin for childhood-onset neuropsychiatric disorders," Biological Psychiatry, vol. 57, no. 7, pp. 788–792, 2005.
[6] G. Moretti, M. Pasquini, G. Mandarelli, L. Tarstani, and M. Biondi, “What every psychiatrist should know about PANDAS: a review,” Clinical Practice and Epidemiology in Mental Health, vol. 4, no. 1, p. 13, 2008.
[7] M. E. Latimer, N. L’Etoile, J. Seidlitz, and S. E. Swedo, "Therapeutic plasma apheresis as a treatment for 35 severely ill children and adolescents with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections," Journal of Child and Adolescent Psychopharmacology, vol. 25, no. 1, pp. 70–75, 2015.
[8] S. M. Bodner, S. A. Morshed, and B. S. Peterson, “The question of PANDAS in adults,” Biological Psychiatry, vol. 49, no. 9, pp. 807–810, 2001.
[9] P. Pavone, R. Bianchini, E. Parano et al., “Anti-brain antibodies in PANDAS versus uncomplicated streptococcal infection,” Pediatric Neurology, vol. 30, no. 2, pp. 107–110, 2004.
[10] J. N. Giedd, J. L. Rapoport, H. L. Leonard, D. Richter, and S. E. Swedo, "Case study: acute basal ganglia enlargement and obsessive–compulsive symptoms in an adolescent boy," Journal of the American Academy of Child and Adolescent Psychiatry, vol. 35, no. 7, pp. 913–915, 1996.
[11] S. J. Perlmutter, S. F. Leitman, M. A. Garvey et al., “Therapeutic plasma exchange and intravenous immunoglobulin for obsessive–compulsive disorder and tic disorders in childhood,” Lancet, vol. 354, no. 9185, pp. 1153–1158, 1999.
[12] G. A. Bernstein, A. M. Victor, A. J. Pipal, and K. A. Williams, "Comparison of clinical characteristics of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and childhood obsessive-compulsive disorder," Journal of Child and Adolescent Psychopharmacology, vol. 20, no. 4, pp. 333–340, 2010.
[13] T. K. Murphy, A. E. Storch, A. B. Lewin, P. J. Edge, and W. K. Goodman, “Clinical factors associated with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections,” The Journal of Pediatrics, vol. 160, no. 2, pp. 314–319, 2012.
[14] T. K. Murphy, A. B. Lewin, E. C. Parker-Athill, E. A. Storch, and P. J. Mutch, “Tonsillectomies and adenoidectomies do not prevent the onset of pediatric autoimmune neuropsychiatric disorder associated with group a streptococcus,” The Pediatric Infectious Disease Journal, vol. 32, no. 8, pp. 834–838, 2013.
[15] G. Vitaliti, O. Tabatabaie, N. Matin et al., “The usefulness of immunotherapy in pediatric neurodegenerative disorders: a systematic review of literature data,” Human Vaccines & Immunotherapeutics, vol. 11, no. 12, pp. 2749–2763, 2015.
[16] D. H. Barzman, H. Jackson, U. Singh, M. Gripp, and J. A. Bernstein, “An atypical presentation of pediatric acute neuropsychiatric syndrome responding to plasmapheresis treatment,” Case Reports in Psychiatry, vol. 2018, Article ID 8189067, 5 pages, 2018.
[17] A. H. Nave, P. Harmel, R. Buchert, and L. Harms, “Altered cerebral glucose metabolism normalized in a patient with a pediatric autoimmune neuropsychiatric disorder after streptococcal infection (PANDAS)-like condition following treatment with plasmapheresis: a case report,” BMC Neurology, vol. 18, no. 1, p. 60, 2018.
[18] J. Elia, M. L. Dell, D. F. Friedman et al., “PANDAS with catatonia: a case report. Therapeutic response to lorazepam and plasmapheresis,” Journal of the American Academy of Child and Adolescent Psychiatry, vol. 44, no. 11, pp. 1145–1150, 2005.